Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (GB:0A4M)
LSE:0A4M
Holding GB:0A4M?
Track your performance easily
0A4M Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$62.40 - $141.97
Previous Close$66.83
Volume9.64K
Average Volume (3M)13.18K
Market Cap
$26.74B
Enterprise Value$28.34B
Total Cash (Recent Filing)$939.20M
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Oct 24, 2024EPS Estimate
$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding400,726,824
10 Day Avg. Volume3,875
30 Day Avg. Volume13,183
Standard Deviation0.32
R-Squared0.01
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)11.21
Price to Sales (P/S)6.99
Price to Cash Flow (P/CF)24.60
P/FCF Ratio31.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.20
Enterprise Value/Gross Profit12.38
Enterprise Value/Ebitda27.45
Forecast
1Y Price Target
$99.94Price Target Upside49.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Dexcom News
PremiumMarket News
SPY ETF Update, 9/26/2024 
PremiumMarket News
QQQ ETF Update, 9/25/2024 
PremiumMarket News
QQQ ETF Update, 9/23/2024 
PremiumMarket News
SPY ETF Update, 9/20/2024 
PremiumMarket News
VOO ETF Update, 9/19/2024 PremiumMarket News
QQQ ETF Update, 9/18/2024 
Bulls Say, Bears Say
Bulls Say
Market PotentialDXCM sees significant room for additional penetration in the diabetes segment and remains confident that CGMs will continue to become the standard of care.
Product LaunchDXCM's 15-day Stelo CGM for non-insulin users was launched in the U.S., marking a significant step in expanding their market reach.
User ExperienceThe app and sensor data for Stelo came already equipped to function within the broader device/health metric ecosystem, enhancing ease of use and integration.
Bears Say
Financial PerformanceDexCom reported a rare topline miss and lowered its FY24 revenue guidance range.
Market ShareNew patient starts in the U.S. fell below expectations due to market share loss.
Sales ForceSales force disruptions and below-expected basal-only new user share vs. ABT impacted U.S. growth.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.79% Insiders
35.06% Mutual Funds
52.44% Other Institutional Investors
9.70% Public Companies and
Individual Investors
0A4M FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest share price was $62.40 and its highest was $141.97 in the past 12 months.
What is Dexcom’s market cap?
Currently, no data Available
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Oct 24, 2024 which is in 28 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Jul 25, 2024. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.386 by $0.044.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is $0.44.
How many shares outstanding does Dexcom have?
Dexcom has 400,726,840 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.43 in its last earnings report, beating expectations of $0.386. Following the earnings report the stock price went down -41.712%.
Which hedge fund is a major shareholder of Dexcom?
Among the largest hedge funds holding Dexcom’s share is Sands Capital Management LLC. It holds Dexcom’s shares valued at 1B.
---
Dexcom Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$99.94 (49.54% Upside)
$99.94 (49.54% Upside)
Blogger Sentiment
Bullish
GB:0A4M Sentiment 84%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.46%
12-Months-Change
Fundamentals
Return on Equity
29.41%
Trailing 12-Months
Asset Growth
-0.32%
Trailing 12-Months
Company Description
Dexcom
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
---
0A4M Company Deck
---
0A4M Earnings Call
Q2 2024
0:00 / 0:00
---
0A4M Revenue Breakdown
72.48% U.S.
27.52% Outside of the U.S.
---
0A4M Stock 12 Month Forecast
Average Price Target
$99.94
▲(49.54% Upside)
Technical Analysis
Best Analysts Covering 0A4M
1 Year
1 Year Success Rate
33/45 ratings generated profit
1 Year Average Return
+38.34%
reiterated a buy rating 11 days ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +38.34% per trade.
---